Online inquiry

IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6633MR)

This product GTTS-WQ6633MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6633MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11577MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ6288MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ5544MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ1396MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ14576MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ15846MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ10279MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ15195MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW